Pharmacological treatment response according to the severity of symptoms in @entity1 with XXXX .

@entity1 @entity1353 @entity1030
BACKGROUND: Pharmacological management of @entity1030 ( @entity1030 ) is recommended according to the individualized assessment of symptoms and exacerbation risks. The aim of this study was to determine the relationship between the baseline Modified British Medical Research Council (mMRC) @entity1353 scale and the @entity1030 Assessment Test (CAT) score and pharmacological treatment response in @entity1 with @entity1030 . METHODS: A total of 102 stable @entity1030 @entity1 who were enrolled in prospective cohort studies were analyzed. Pharmacological treatment responses after a 3-month treatment were assessed by changes on the mMRC @entity1353 scale, CAT scores, and spirometric pulmonary functions. RESULTS: Sixty-two @entity1 with a mMRC @entity1353 scale  <=1 were classified as having "less @entity1353 " and 40 @entity1 with a mMRC @entity1353 scale >= 2 as having "more @entity1353 ". After a 3-month treatment, the mean mMRC @entity1353 scale in the "more @entity1353 " group was significantly decreased versus the "less @entity1353 " group; however, there were no significant differences in CAT score changes or spirometric pulmonary function changes between the two groups. Baseline mMRC scales (Spearman's rho =-0.591, P<0.001) and baseline CAT scores (Pearson's r =-0.337, P=0.001) were significantly correlated with their changes after a 3-month treatment. Multiple logistic regression analysis demonstrated that baseline mMRC scale and CAT score were the only independent predictors of improvement greater than a minimal clinically significant difference after treatment. CONCLUSIONS: The severity of @entity1030 symptoms is associated with their response to pharmacotherapy. @entity1030 @entity1 with a higher baseline mMRC @entity1353 scale and CAT score experience greater symptom reduction by pharmacotherapy.
